[HTML][HTML] Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
M Talmon, M Percio, JA Obeng, FA Ruffinatti, D Sola… - PLoS …, 2023 - journals.plos.org
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
[HTML][HTML] Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
M Talmon, M Percio, JA Obeng, FA Ruffinatti, D Sola… - PLOS …, 2023 - ncbi.nlm.nih.gov
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
M Talmon, M Percio, JA Obeng, FA Ruffinatti, D Sola… - PLOS ONE, 2023 - iris.uniupo.it
: It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
M Talmon, M Percio, JA Obeng, FA Ruffinatti, D Sola… - PLoS ONE, 2023 - research.uniupo.it
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab.
M Talmon, M Percio, JA Obeng, FA Ruffinatti, D Sola… - Plos one, 2023 - europepmc.org
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab.
M Talmon, M Percio, JA Obeng, FA Ruffinatti… - PLoS …, 2023 - search.ebscohost.com
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
M Talmon, M Percio, JA Obeng, FA Ruffinatti, D Sola… - PLOS ONE, 2023 - iris.unito.it
: It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
M Talmon, M Percio, JA Obeng, FA Ruffinatti… - PLoS …, 2023 - ui.adsabs.harvard.edu
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
M Talmon, M Percio, JA Obeng, FA Ruffinatti… - PloS …, 2023 - pubmed.ncbi.nlm.nih.gov
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
M Talmon, M Percio, JA Obeng, FA Ruffinatti, D Sola… - PLoS ONE, 2023 - research.uniupo.it
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct
susceptibility to the different biologic DMARDs available on the market, probably because of …
susceptibility to the different biologic DMARDs available on the market, probably because of …